Cargando…
Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria
Ravulizumab is an anti-C5 antibody approved for treating paroxysmal nocturnal hemoglobinuria (PNH). In August 2019, a 77-year-old Japanese man with PNH, who had been on ravulizumab treatment for 2 years, was hospitalized for chest discomfort and malaise. Electrocardiography identified a right bundle...
Autores principales: | Takahashi, Hiroshi, Mori, Hirotaka, Fukatsu, Masahiko, Sano, Takahiro, Harada, Kayo, Oikawa, Masayoshi, Takeishi, Yasuchika, Kimura, Satoshi, Ohkawara, Hiroshi, Shichishima, Tsutomu, Ikezoe, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Fukushima Society of Medical Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840890/ https://www.ncbi.nlm.nih.gov/pubmed/36130907 http://dx.doi.org/10.5387/fms.2022-16 |
Ejemplares similares
-
Independent Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Syndrome Clones in a Patient With Complete Bone Marrow Failure
por: Mita, Masayuki, et al.
Publicado: (2018) -
Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
por: Gurnari, Carmelo, et al.
Publicado: (2021) -
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
por: Stern, Robert M., et al.
Publicado: (2019) -
No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020) -
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
por: Quist, S. W., et al.
Publicado: (2023)